Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy

F. Semeraro, A. Cancarini, F. Morescalchi, M. R. Romano, R. dell'Omo, G. Ruggeri, L. Agnifili, C. Costagliola

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Aim: This study compared systemic and intraocular concentrations of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in patients with type 2 diabetes (T2D) and proliferative diabetic retinopathy (PDR) with levels in patients without diabetes, and looked for possible correlations between the concentrations found and other variables analyzed. Methods: Concentrations of EPO and VEGF were measured in the aqueous and vitreous humours and serum of patients undergoing vitrectomy for PDR (33 patients) or for macular holes or puckers (20 control patients). EPO was assayed by radioimmunoassay, with a lower limit of detection (LOD) of 1.0 mIU/mL. VEGF was assayed using enzyme-linked immunosorbent assay (ELISA), with a lower LOD of 10.0. pg/mL. Results: EPO concentrations in serum did not differ significantly between the two groups, whereas EPO in vitreous and aqueous were higher in diabetic than in non-diabetic patients. VEGF in serum was lower in diabetic patients than in non-diabetics; conversely, VEGF concentrations in vitreous were significantly higher in diabetic patients. A direct correlation was found between vitreous and aqueous EPO concentrations, and between vitreous EPO and blood glucose concentrations. A significant, negative correlation between vitreous EPO concentration and age was also recorded. Conclusion: High EPO concentrations in the vitreous of patients with PDR and its correlation with blood glucose suggest that EPO could play a role in the pathogenesis of PDR. All possible factors affecting serum and ocular concentrations of EPO and VEGF should be determined to identify compounds able to prevent and control this serious microvascular complication of diabetes.

Original languageEnglish
Pages (from-to)445-451
Number of pages7
JournalDiabetes and Metabolism
Volume40
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Erythropoietin
Type 2 Diabetes Mellitus
Vascular Endothelial Growth Factor A
Serum
Diabetic Retinopathy
Blood Glucose
Limit of Detection
Vitreous Body
Retinal Perforations
Aqueous Humor
Vitrectomy
Diabetes Complications
Radioimmunoassay
Enzyme-Linked Immunosorbent Assay

Keywords

  • Diabetes mellitus
  • Diabetic retinopathy
  • Erythropoiesis stimulating agents
  • Erythropoietin
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. / Semeraro, F.; Cancarini, A.; Morescalchi, F.; Romano, M. R.; dell'Omo, R.; Ruggeri, G.; Agnifili, L.; Costagliola, C.

In: Diabetes and Metabolism, Vol. 40, No. 6, 01.12.2014, p. 445-451.

Research output: Contribution to journalArticle

Semeraro, F, Cancarini, A, Morescalchi, F, Romano, MR, dell'Omo, R, Ruggeri, G, Agnifili, L & Costagliola, C 2014, 'Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy', Diabetes and Metabolism, vol. 40, no. 6, pp. 445-451. https://doi.org/10.1016/j.diabet.2014.04.005
Semeraro, F. ; Cancarini, A. ; Morescalchi, F. ; Romano, M. R. ; dell'Omo, R. ; Ruggeri, G. ; Agnifili, L. ; Costagliola, C. / Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. In: Diabetes and Metabolism. 2014 ; Vol. 40, No. 6. pp. 445-451.
@article{9da5fa6c6466401e9396a83594dff4d0,
title = "Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy",
abstract = "Aim: This study compared systemic and intraocular concentrations of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in patients with type 2 diabetes (T2D) and proliferative diabetic retinopathy (PDR) with levels in patients without diabetes, and looked for possible correlations between the concentrations found and other variables analyzed. Methods: Concentrations of EPO and VEGF were measured in the aqueous and vitreous humours and serum of patients undergoing vitrectomy for PDR (33 patients) or for macular holes or puckers (20 control patients). EPO was assayed by radioimmunoassay, with a lower limit of detection (LOD) of 1.0 mIU/mL. VEGF was assayed using enzyme-linked immunosorbent assay (ELISA), with a lower LOD of 10.0. pg/mL. Results: EPO concentrations in serum did not differ significantly between the two groups, whereas EPO in vitreous and aqueous were higher in diabetic than in non-diabetic patients. VEGF in serum was lower in diabetic patients than in non-diabetics; conversely, VEGF concentrations in vitreous were significantly higher in diabetic patients. A direct correlation was found between vitreous and aqueous EPO concentrations, and between vitreous EPO and blood glucose concentrations. A significant, negative correlation between vitreous EPO concentration and age was also recorded. Conclusion: High EPO concentrations in the vitreous of patients with PDR and its correlation with blood glucose suggest that EPO could play a role in the pathogenesis of PDR. All possible factors affecting serum and ocular concentrations of EPO and VEGF should be determined to identify compounds able to prevent and control this serious microvascular complication of diabetes.",
keywords = "Diabetes mellitus, Diabetic retinopathy, Erythropoiesis stimulating agents, Erythropoietin, Vascular endothelial growth factor",
author = "F. Semeraro and A. Cancarini and F. Morescalchi and Romano, {M. R.} and R. dell'Omo and G. Ruggeri and L. Agnifili and C. Costagliola",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.diabet.2014.04.005",
language = "English",
volume = "40",
pages = "445--451",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy

AU - Semeraro, F.

AU - Cancarini, A.

AU - Morescalchi, F.

AU - Romano, M. R.

AU - dell'Omo, R.

AU - Ruggeri, G.

AU - Agnifili, L.

AU - Costagliola, C.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aim: This study compared systemic and intraocular concentrations of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in patients with type 2 diabetes (T2D) and proliferative diabetic retinopathy (PDR) with levels in patients without diabetes, and looked for possible correlations between the concentrations found and other variables analyzed. Methods: Concentrations of EPO and VEGF were measured in the aqueous and vitreous humours and serum of patients undergoing vitrectomy for PDR (33 patients) or for macular holes or puckers (20 control patients). EPO was assayed by radioimmunoassay, with a lower limit of detection (LOD) of 1.0 mIU/mL. VEGF was assayed using enzyme-linked immunosorbent assay (ELISA), with a lower LOD of 10.0. pg/mL. Results: EPO concentrations in serum did not differ significantly between the two groups, whereas EPO in vitreous and aqueous were higher in diabetic than in non-diabetic patients. VEGF in serum was lower in diabetic patients than in non-diabetics; conversely, VEGF concentrations in vitreous were significantly higher in diabetic patients. A direct correlation was found between vitreous and aqueous EPO concentrations, and between vitreous EPO and blood glucose concentrations. A significant, negative correlation between vitreous EPO concentration and age was also recorded. Conclusion: High EPO concentrations in the vitreous of patients with PDR and its correlation with blood glucose suggest that EPO could play a role in the pathogenesis of PDR. All possible factors affecting serum and ocular concentrations of EPO and VEGF should be determined to identify compounds able to prevent and control this serious microvascular complication of diabetes.

AB - Aim: This study compared systemic and intraocular concentrations of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in patients with type 2 diabetes (T2D) and proliferative diabetic retinopathy (PDR) with levels in patients without diabetes, and looked for possible correlations between the concentrations found and other variables analyzed. Methods: Concentrations of EPO and VEGF were measured in the aqueous and vitreous humours and serum of patients undergoing vitrectomy for PDR (33 patients) or for macular holes or puckers (20 control patients). EPO was assayed by radioimmunoassay, with a lower limit of detection (LOD) of 1.0 mIU/mL. VEGF was assayed using enzyme-linked immunosorbent assay (ELISA), with a lower LOD of 10.0. pg/mL. Results: EPO concentrations in serum did not differ significantly between the two groups, whereas EPO in vitreous and aqueous were higher in diabetic than in non-diabetic patients. VEGF in serum was lower in diabetic patients than in non-diabetics; conversely, VEGF concentrations in vitreous were significantly higher in diabetic patients. A direct correlation was found between vitreous and aqueous EPO concentrations, and between vitreous EPO and blood glucose concentrations. A significant, negative correlation between vitreous EPO concentration and age was also recorded. Conclusion: High EPO concentrations in the vitreous of patients with PDR and its correlation with blood glucose suggest that EPO could play a role in the pathogenesis of PDR. All possible factors affecting serum and ocular concentrations of EPO and VEGF should be determined to identify compounds able to prevent and control this serious microvascular complication of diabetes.

KW - Diabetes mellitus

KW - Diabetic retinopathy

KW - Erythropoiesis stimulating agents

KW - Erythropoietin

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84919695236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919695236&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2014.04.005

DO - 10.1016/j.diabet.2014.04.005

M3 - Article

VL - 40

SP - 445

EP - 451

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 6

ER -